VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer
VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.
VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone
VolitionRx Limited to Attend Conferences in December
Singapore Volition signs Memorandum of Understanding with the National Taiwan University to Conduct Two Large Clinical Studies
VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update
VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update
VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits
VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding
VolitionRx Announces its European Colorectal Cancer Strategy
